MOTS, US62014P5044

Motus GI Holdings stock sits beside Pure-Vu data from 38 to 96 percent

Published on 10/16/2026 at 00:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pure-Vu cites 38 percent to 96 percent better visualization on the company site. Motus GI Holdings stock has November 17, 2026 earnings.

Product evidence and corporate status

Motus GI's Pure-Vu website cites visualization improvement from 38 percent to 96 percent.
The next earnings date is November 17, 2026, according to a dated financial calendar.
Motus GI entered Chapter 11 proceedings in 2024 before selling major assets.

MOTS, US62014P5044, Illustration mit AI erstellt.

Motus GI Holdings stock sits beside Pure-Vu data citing a 38 percent to 96 percent improvement in visualization. The company website presents the device as a tool for upper gastrointestinal endoscopy and colonoscopy procedures.

Pure-Vu remains the product anchor

Motus GI's website describes Pure-Vu as a system designed to improve visualization when blood, clots or other debris compromise an endoscopic examination. The company links the product to a 38 percent to 96 percent improvement in visualization, making that range the clearest operating figure in the current company narrative.

The product is presented as a procedure-support device rather than a replacement for standard endoscopes. That positioning keeps the investment story tied to clinical use and the fate of the underlying technology.

What defines the current product case?

The key question is whether Pure-Vu's reported visualization benefit can translate into a continuing commercial role. The company website identifies upper gastrointestinal endoscopy and colonoscopy as target procedures, while the 38 percent to 96 percent range supplies the measurable product comparison.

ARIVA states that Motus GI entered Chapter 11 proceedings in 2024 and sold major assets, including the Pure-Vu technology, while the listed entity remained as a corporate shell. That history places the product evidence in a restructuring context rather than alongside a conventional growth report.

Next date is November 17, 2026

The next dated company event is the earnings date of November 17, 2026, listed by Forecaster. That date is the next calendar marker for investors following the status of the listed entity and the Pure-Vu assets.

Legacy status shapes the outlook

Motus GI's historical business centered on gastrointestinal endoscopy, but the Chapter 11 process and asset sale changed the relevance of earlier operating assumptions. The remaining investor question is therefore tied to corporate status, asset ownership and any disclosures accompanying the November 17, 2026 reporting date.

Company facts

Motus GI Holdings develops medical devices for gastrointestinal endoscopy, with Pure-Vu as its named product. The company website identifies a visualization improvement range of 38 percent to 96 percent, while the next earnings date is November 17, 2026.